Literature DB >> 26520650

Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.

Kunio Kitamura1, Takahiro Nishiyama2,3, Ken Ishiyama4,5, Shuichi Miyawaki4, Kanji Miyazaki6, Kenshi Suzuki6, Hiroaki Masaie7, Masaya Okada8, Hiroyasu Ogawa8, Kiyotoshi Imai9, Hitoshi Kiyoi3, Tomoki Naoe3,10, Yasuhisa Yokoyama11, Shigeru Chiba11, Tomoko Hata12, Yasushi Miyazaki12, Yoshihiro Hatta13, Jin Takeuchi13,14, Yasuhito Nannya15, Mineo Kurokawa15, Yasunori Ueda16, Daisuke Koga17, Haruo Sugiyama18, Fumimaro Takaku19.   

Abstract

We have previously shown the clinical usefulness of Wilms' tumor 1 gene (WT1) mRNA expression in peripheral blood (PB) as a minimal residual disease (MRD) monitoring marker in 191 acute myeloid leukemia (AML) patients using the WT1 mRNA assay kit "Otsuka" (Otsuka Pharmaceutical Co., Ltd.; "former kit"). In contrast, the usefulness of WT1 mRNA expression in bone marrow (BM) has been investigated in only a limited number of subjects using former kit. Following that previous study, a next-generation kit, WT1 mRNA assay kit II "Otsuka" (Otsuka Pharmaceutical Co., Ltd.; "new kit") has been newly developed. In the present study, we aimed to evaluate the performance of the new kit and to investigate the clinical usefulness of WT1 mRNA expression in BM. The PB and BM were collected on the same day from 164 blood disease patients, including 118 AML patients. WT1 mRNA expression was determined using the new and former kits and the values obtained were compared. The performance of new kit was shown to be equivalent to that of former kit. As reported in PB, WT1 mRNA expression in BM was found to be a useful marker for monitoring disease status as well as for a diagnosis of early stage relapse in AML patients.

Entities:  

Keywords:  Acute myeloid leukemia; Bone marrow; Myelodysplastic syndromes; One step real-time RT-PCR; WT1 mRNA

Mesh：

Substances：

Year:  2015        PMID： 26520650     DOI： 10.1007/s12185-015-1882-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  17 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.

Authors:  M Weisser; W Kern; S Rauhut; C Schoch; W Hiddemann; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

3.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

Authors:  K M Call; T Glaser; C Y Ito; A J Buckler; J Pelletier; D A Haber; E A Rose; A Kral; H Yeger; W H Lewis
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

4.  [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].

Authors:  Shuichi Miyawaki; Nobuhiko Emi; Kinuko Mitani; Kazuma Oyashiki; Kuniaki Kitamura; Takehisa Morishita; Hiroyasu Ogawa; Norio Komatsu; Toshihiro Soma; Toshiharu Tamaki; Hirofumi Kosugi; Kazunori Ohnishi; Hideaki Mizoguchi; Akira Hiraoka; Yoshinao Kodera; Ryuzo Ueda; Yasuo Morishima; Masashi Nakagawa; Tadashi Tobita; Koichi Sugimoto; Shigeru Chiba; Nobumasa Inoue; Motohiro Hamaguchi; Daisuke Koga; Hiroya Tamaki; Tomoki Naoe; Haruo Sugiyama; Fumimaro Takaku
Journal:  Rinsho Ketsueki       Date:  2005-12

5.  Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).

Authors:  Hiroya Tamaki; Machiko Mishima; Manabu Kawakami; Akihiro Tsuboi; Eui Ho Kim; Naoki Hosen; Kazuhiro Ikegame; Masaki Murakami; Tatsuya Fujioka; Tomoki Masuda; Yuki Taniguchi; Sumiyuki Nishida; Kazuoki Osumi; Toshihiro Soma; Yusuke Oji; Yoshihiro Oka; Ichiro Kawase; Haruo Sugiyama; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

6.  WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.

Authors:  Mette Østergaard; Lene Hyldahl Olesen; Henrik Hasle; Eigil Kjeldsen; Peter Hokland
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

Review 7.  The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.

Authors:  F J Rauscher
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

8.  Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.

Authors:  J Trka; M Kalinová; O Hrusák; J Zuna; O Krejcí; J Madzo; P Sedlácek; V Vávra; K Michalová; M Jarosová; J Starý
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

9.  Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.

Authors:  Hans Beier Ommen; Charlotte Guldborg Nyvold; Karin Braendstrup; Bodil Lind Andersen; Ingrid Beier Ommen; Henrik Hasle; Peter Hokland; Mette Ostergaard
Journal:  Br J Haematol       Date:  2008-04-10       Impact factor: 6.998

10.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02
View more
  3 in total

1.  Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

Authors:  David A Jacobsohn; Michael R Loken; Mingwei Fei; Alexia Adams; Lisa Eidenschink Brodersen; Brent R Logan; Kwang Woo Ahn; Bronwen E Shaw; Morris Kletzel; Marie Olszewski; Sana Khan; Soheil Meshinchi; Amy Keating; Andrew Harris; Pierre Teira; Reggie E Duerst; Steven P Margossian; Paul L Martin; Aleksandra Petrovic; Christopher C Dvorak; Eneida R Nemecek; Michael W Boyer; Allen R Chen; Jeffrey H Davis; Shalini Shenoy; Sureyya Savasan; Michelle P Hudspeth; Roberta H Adams; Victor A Lewis; Albert Kheradpour; Kimberly A Kasow; Alfred P Gillio; Ann E Haight; Monica Bhatia; Barbara J Bambach; Hilary L Haines; Troy C Quigg; Robert J Greiner; Julie-An M Talano; David C Delgado; Alexandra Cheerva; Madhu Gowda; Sanjay Ahuja; Mehmet Ozkaynak; David Mitchell; Kirk R Schultz; Terry J Fry; David M Loeb; Michael A Pulsipher
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-19       Impact factor: 5.742

2.  Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group.

Authors:  Wataru Kitamura; Nobuharu Fujii; Yuichiro Nawa; Keigo Fujishita; Hiroyuki Sugiura; Takanori Yoshioka; Yuki Fujiwara; Yoshiaki Usui; Keiko Fujii; Hideaki Fujiwara; Noboru Asada; Hisakazu Nishimori; Ken-Ichi Matsuoka; Yoshinobu Maeda
Journal:  Int J Hematol       Date:  2022-02-04       Impact factor: 2.490

3.  Prognostic impact of peripheral blood Wilms' tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis.

Authors:  Tomoya Maeda; Akira Matsuda; Chie Asou; Daisuke Okamura; Ken Tanae; Mika Kohri; Maho Ishikawa; Naoki Takahashi; Kunihiro Tsukasaki; Nobutaka Kawai; Norio Asou; Masami Bessho
Journal:  Leuk Res Rep       Date:  2020-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.